Q-omics provides the consensus-scored ELOCP33 profile across patient tissues and cancer cell-line models. ELOCP33 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ELOCP33 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, ELOCP33 RNA expression shows 6,467 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where ELOCP33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP33 survival associations across molecular data types. ELOCP33 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP33 RNA expression–survival associations across cancer types. High ELOCP33 expression shows unfavorable associations in ACC, KIRC and DLBC, but favorable associations in CHOL, LUAD and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify ACC as the clearest survival context for ELOCP33 RNA expression.
This table summarizes ELOCP33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP33 shows lower tumor expression in LUAD and higher tumor expression in BRCA and LIHC. The BRCA box plot shows higher ELOCP33 RNA expression in tumor versus normal tissue (log2 FC = +0.137, t-test p = .044).
This table shows molecular features associated with ELOCP33 in patient tissues and cancer cell lines. In patient samples, ELOCP33 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
